5.35
price up icon1.52%   0.08
after-market Dopo l'orario di chiusura: 5.39 0.04 +0.75%
loading
Precedente Chiudi:
$5.27
Aprire:
$5.275
Volume 24 ore:
522.70K
Relative Volume:
0.24
Capitalizzazione di mercato:
$293.98M
Reddito:
$3.64M
Utile/perdita netta:
$-87.37M
Rapporto P/E:
-1.3017
EPS:
-4.11
Flusso di cassa netto:
$-86.46M
1 W Prestazione:
+1.90%
1M Prestazione:
+15.80%
6M Prestazione:
-4.29%
1 anno Prestazione:
+49.03%
Intervallo 1D:
Value
$5.265
$5.40
Intervallo di 1 settimana:
Value
$4.86
$5.57
Portata 52W:
Value
$2.10
$9.10

Verastem Inc Stock (VSTM) Company Profile

Name
Nome
Verastem Inc
Name
Telefono
(781) 292-4200
Name
Indirizzo
117 KENDRICK STREET, NEEDHAM, MA
Name
Dipendente
78
Name
Cinguettio
@VerastemOncolog
Name
Prossima data di guadagno
2024-11-06
Name
Ultimi documenti SEC
Name
VSTM's Discussions on Twitter

Confronta VSTM con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
VSTM
Verastem Inc
5.35 289.58M 3.64M -87.37M -86.46M -4.11
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
476.95 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.39 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.64 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
575.42 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.83 31.99B 3.81B -644.79M -669.77M -6.24

Verastem Inc Stock (VSTM) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-10 Iniziato Jefferies Buy
2025-03-24 Reiterato H.C. Wainwright Buy
2024-12-31 Reiterato BTIG Research Buy
2024-09-30 Iniziato Guggenheim Buy
2023-11-21 Ripresa BTIG Research Buy
2023-09-27 Iniziato B. Riley Securities Buy
2023-06-15 Aggiornamento Mizuho Neutral → Buy
2022-09-07 Ripresa Alliance Global Partners Buy
2022-04-29 Ripresa Cantor Fitzgerald Overweight
2022-04-14 Iniziato RBC Capital Mkts Outperform
2022-03-09 Iniziato Truist Buy
2021-07-01 Iniziato Alliance Global Partners Buy
2021-05-24 Aggiornamento BTIG Research Neutral → Buy
2019-06-20 Downgrade BTIG Research Buy → Neutral
2019-05-10 Downgrade Raymond James Outperform → Mkt Perform
2018-07-13 Iniziato BTIG Research Buy
2018-05-02 Iniziato Seaport Global Securities Buy
2018-03-08 Iniziato B. Riley FBR, Inc. Buy
2017-09-07 Reiterato H.C. Wainwright Buy
2017-04-13 Iniziato Oppenheimer Outperform
2017-03-24 Reiterato H.C. Wainwright Buy
2015-09-29 Downgrade Cantor Fitzgerald Buy → Hold
2015-09-29 Downgrade JMP Securities Mkt Outperform → Mkt Perform
2015-09-29 Downgrade Jefferies Buy → Hold
2015-09-29 Downgrade Raymond James Strong Buy → Outperform
2015-09-28 Downgrade Mizuho Buy → Neutral
2015-09-28 Downgrade ROTH Capital Buy → Neutral
2015-09-09 Iniziato Raymond James Strong Buy
2015-05-12 Reiterato UBS Buy
2015-04-08 Iniziato H.C. Wainwright Buy
2015-01-23 Reiterato ROTH Capital Buy
2014-07-08 Ripresa Oppenheimer Perform
2014-02-11 Iniziato Mizuho Buy
Mostra tutto

Verastem Inc Borsa (VSTM) Ultime notizie

pulisher
Jul 23, 2025

Published on: 2025-07-24 00:31:57 - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Is Verastem Inc. a good long term investmentConsistent high-yield stocks - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds - The Malaysian Reserve

Jul 23, 2025
pulisher
Jul 23, 2025

High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds - Benzinga

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about Verastem Inc. stockFree Expert Stock Watchlist - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

What drives Verastem Inc. stock priceUnmatched profit potential - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

Verastem Inc. Stock Analysis and ForecastMarket-beating returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

(VSTM) Proactive Strategies - news.stocktradersdaily.com

Jul 22, 2025
pulisher
Jul 18, 2025

Verastem’s Promising KRAS G12D Inhibitor Study: A Potential Game-Changer in Cancer Treatment - TipRanks

Jul 18, 2025
pulisher
Jul 16, 2025

Verastem: The Market Is Ignoring The Progress (NASDAQ:VSTM) - Seeking Alpha

Jul 16, 2025
pulisher
Jul 16, 2025

Why Verastem Inc. stock attracts strong analyst attentionDaily Trade Opportunity - beatles.ru

Jul 16, 2025
pulisher
Jul 15, 2025

What makes Verastem Inc. stock price move sharplyEntry Level Low Risk Picks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Verastem Inc. stock performs during market volatilityFast Moving Stock Alerts - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

Avutometinib-Defactinib: A New Standard in Precision Oncology? - AInvest

Jul 14, 2025
pulisher
Jul 14, 2025

Verastem’s avutometinib combination shows 31% ORR in ovarian cancer trial - Yahoo Finance

Jul 14, 2025
pulisher
Jul 11, 2025

Verastem Oncology's Breakthrough in LGSOC: A New Standard of Care with Substantial Upside Potential - AInvest

Jul 11, 2025
pulisher
Jul 11, 2025

Verastem’s cancer drug shows 31% response rate in ovarian cancer trial By Investing.com - Investing.com Canada

Jul 11, 2025
pulisher
Jul 11, 2025

Verastem stock rises after LGSOC treatment data published in medical journal - Investing.com

Jul 11, 2025
pulisher
Jul 11, 2025

Verastem stock rises after LGSOC treatment data published in medical journal By Investing.com - Investing.com South Africa

Jul 11, 2025
pulisher
Jul 11, 2025

Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology - Yahoo Finance

Jul 11, 2025
pulisher
Jul 10, 2025

KRAS Inhibitors Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Target Population, Revenue, Statistics, MOA, ROA and Companies DelveInsight - Barchart.com

Jul 10, 2025
pulisher
Jul 08, 2025

Verastem Oncology's Talent Incentives: Balancing Equity Dilution and Growth - AInvest

Jul 08, 2025
pulisher
Jul 08, 2025

Verastem Oncology announces inducement grants under Nasdaq listing rule - MarketScreener

Jul 08, 2025
pulisher
Jul 08, 2025

Verastem Oncology Awards 45,000 Share Options at $4.29 Each to Expand Cancer Drug Development Team - Stock Titan

Jul 08, 2025
pulisher
Jul 04, 2025

Verastem’s Phase 3 Study on Avutometinib and Defactinib: A Potential Game-Changer for Ovarian Cancer Treatment - TipRanks

Jul 04, 2025
pulisher
Jul 02, 2025

Verastem’s Promising Phase 3 Study on Recurrent Ovarian Cancer - TipRanks

Jul 02, 2025
pulisher
Jul 01, 2025

How the (VSTM) price action is used to our Advantage - news.stocktradersdaily.com

Jul 01, 2025
pulisher
Jun 30, 2025

Verastem’s Promising Phase 3 Study on Avutometinib and Defactinib in Ovarian Cancer - TipRanks

Jun 30, 2025
pulisher
Jun 28, 2025

Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World

Jun 28, 2025
pulisher
Jun 26, 2025

Verastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related Cancers - Seeking Alpha

Jun 26, 2025
pulisher
Jun 25, 2025

Verastem (VSTM) Target Price Lowered by RBC Capital | VSTM Stock News - GuruFocus

Jun 25, 2025
pulisher
Jun 25, 2025

RBC Capital Adjusts Target Price for Verastem (VSTM) to $12 | VS - GuruFocus

Jun 25, 2025
pulisher
Jun 25, 2025

RBC Capital Adjusts Target Price for Verastem (VSTM) to $12 | VSTM Stock News - GuruFocus

Jun 25, 2025
pulisher
Jun 25, 2025

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors - BioSpace

Jun 25, 2025
pulisher
Jun 24, 2025

Verastem Executives Sell Shares to Meet Tax Obligations - TradingView

Jun 24, 2025

Verastem Inc Azioni (VSTM) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$22.87
price up icon 4.91%
$36.01
price down icon 0.25%
$103.44
price up icon 0.51%
$28.01
price up icon 5.54%
$114.60
price up icon 2.84%
biotechnology ONC
$294.83
price down icon 0.26%
Capitalizzazione:     |  Volume (24 ore):